HINDHealthcare · BiotechnologyThe 3 Wall Street analysts covering Vyome Holdings, Inc. hold a median 12-month price target of $8 — +406.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Vyome Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HIND, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +406.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Sept 2026 | Chardan Capital | Initiates | Buy | $3.50 |
| 2 Oct 2025 | Maxim Group | Assumes | Buy | $15 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HIND appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 4% of US stocks
Cheaper than 44% of US stocks
Cheaper than 71% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Higher than 54% of US stocks
Higher than 3% of US stocks
Higher than 97% of US stocks
Higher than 2% of US stocks
Higher than 8% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vyome Holdings, Inc. has a market value of $11.4M and an enterprise value of $4.8M.
Revenue in the twelve months to 30 June 2026: $130K. The latest quarter shrank 46.0% year on year.
Net income over the same four quarters: −$11.6M, a −8926.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$5.6M.
Trailing P/E: 0.9×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vyome Holdings, Inc. employs 9 people — $14K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vyome Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Vyome Holdings congratulated Scientific Co-Founder and Director Dr. Shiladitya Sengupta on his promotion to Professor of Medicine at Harvard Medical School. The company described the promotion as a milestone in his scientific career.
Why it matters — HIND watchers may note the academic recognition of a Vyome co-founder and director.
Vyome Holdings, Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303, titled "Formulations and Method for Treatment of Inflammatory Diseases." The allowed claims cover its novel topical mycophenolate program, VT-1908, which targets the ocular inflammation market.
Why it matters — The Notice of Allowance strengthens intellectual-property protection for Vyome's VT-1908 program, a key asset in its pipeline targeting the large ocular inflammation market.
Vyome Holdings, Inc. announced the appointment of Jerry Leonard, CPA, MBA, as Chief Financial Officer, effective September 1, 2026. Leonard will oversee the company's financial operations, financial reporting, and accounting functions.
Why it matters — HIND watchers would note the appointment of an experienced public company finance executive to oversee the company's financial operations.
The 3 Wall Street analysts covering Vyome Holdings, Inc. have a median 12-month price target of $8, with estimates ranging from $3.5 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Vyome Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vyome Holdings, Inc. 27 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Vyome Holdings, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +406.3% from the last close, and Ticker Nerd's factor model ranks Vyome Holdings, Inc. 27 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vyome Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HIND are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $15 over the next 12 months.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
The most recent item we track (Business Wire, 26 Oct 2026): "Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School". Vyome Holdings congratulated Scientific Co-Founder and Director Dr. Shiladitya Sengupta on his promotion to Professor of Medicine at Harvard Medical School. The company described the promotion as a milestone in his scientific career.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
CEO Mr. Venkateswarlu Nelabhotla M.B.A. · 9 employees · United States · https://www.vyometx.com